Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.51 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092244 | 0.87 | MGAT2 (0.65) | MAOAMAOBALDH1A1KDM4ELMNA | |
| SCHEMBL1091461 | 0.81 | CA12 (0.55) | MAOAMAOBALDH1A1KDM4ETSHR | |
| SCHEMBL17085971 | 0.79 | KMT2A (0.52) | PRMT1TAAR1HSD17B10ALDH1A1KDM4E | |
| SCHEMBL29441693 | 0.79 | KMT2A (0.52) | PRMT1TAAR1HSD17B10ALDH1A1KDM4E | |
| SCHEMBL14111831 | 0.78 | ALDH1A1 (0.67) | ALDH1A1KDM4ELMNATSHRPOLB | |
| SCHEMBL14111818 | 0.78 | CASP3 (0.54) | MAOAMAOBALDH1A1TSHR | |
| SCHEMBL15668360 | 0.78 | PKM (0.58) | PRMT1TAAR1HSD17B10ALDH1A1KDM4E | |
| SCHEMBL6535436 | 0.75 | CASP3 (0.67) | MAOAMAOBALDH1A1MAPK1 | |
| SCHEMBL6536067 | 0.75 | CA12 (0.54) | MAOAMAOBTSHRMAPK1 | |
| SCHEMBL4411616 | 0.74 | POLB (0.62) | MAOAMAOBHSD17B10ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | MAOA 4821/4885MAOB 4817/4885PRMT1 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.